07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
07:00 , May 21, 2012 |  BioCentury  |  Emerging Company Profile

Amakem: Switching off side effects

Amakem N.V. is using its localized drug action technology to reduce the side effects of treatments for ophthalmic diseases. The company hopes to establish proof of principle for the technology with a Rho kinase inhibitor...
07:00 , Oct 6, 2011 |  BC Innovations  |  Targets & Mechanisms

ROCKing in hematology

A team at the Indiana University School of Medicine has published the first evidence that rho kinase inhibitors could help treat acute myelogenous leukemia and other hematological malignancies. 1 The researchers now hope to repurpose...